|1.||Kluger, Jeffrey: 7 articles (07/2009 - 03/2003)|
|2.||White, C Michael: 6 articles (11/2007 - 03/2003)|
|3.||Khan, Ijaz A: 5 articles (07/2004 - 11/2002)|
|4.||Vasavada, Balendu C: 5 articles (07/2004 - 11/2002)|
|5.||Gowda, Ramesh M: 5 articles (07/2004 - 11/2002)|
|6.||Sacchi, Terrence J: 5 articles (07/2004 - 11/2002)|
|7.||Coleman, Craig I: 4 articles (07/2009 - 01/2004)|
|8.||Wilbur, Sabrina L: 4 articles (07/2004 - 07/2003)|
|9.||Punukollu, Gopikrishna: 4 articles (06/2004 - 11/2002)|
|10.||Kalus, James S: 4 articles (04/2004 - 03/2003)|
01/01/2009 - "Acute beta-adrenoceptor blockade improves efficacy of ibutilide in conversion of atrial fibrillation with a rapid ventricular rate."
02/01/2005 - "Ibutilide is an intravenous class III antiarrhythmic agent that has been shown to be effective in converting acute onset atrial fibrillation/flutter in stable medical and cardio-surgical patients. "
03/01/2004 - "Ibutilide appears to be an effective drug for conversion of recent-onset atrial fibrillation and flutter in elderly patients under monitored conditions. "
08/15/1997 - "Ibutilide is an intravenous, selective class III antiarrhythmic agent that is effective for conversion of atrial fibrillation or flutter. "
01/01/2011 - "This article reviews the safety and efficacy of ibutilide for use in patients with atrial fibrillation and flutter. "
|2.||Atrial Flutter (Flutter, Atrial)
01/01/2005 - "Ibutilide is highly effective for rapidly terminating atrial flutter. "
02/01/2004 - "Ibutilide is particularly effective in rapid termination of atrial flutter (AFL) with few adverse effects. "
01/01/2002 - "Ibutilide appears to be an effective and well tolerated drug for rapid conversion of recent-onset atrial flutter in octogenarian patients, and may represent a valid approach in the acute management of atrial flutter in this particular set of patients."
05/01/1998 - "Ibutilide fumarate is an intravenous (IV) class III antiarrhythmic agent that has been shown to be significantly more effective than placebo in the pharmacologic conversion of atrial flutter and fibrillation to sinus rhythm. "
07/01/1993 - "The results demonstrate oral efficacy of ibutilide with rapid onset of action (in 30-60 min), resulting in increased AERP and prevention of induced atrial flutter in this model."
|3.||Cardiac Arrhythmias (Arrythmia)
03/29/2001 - "Progress toward the development of a safe and effective agent for treating reentrant cardiac arrhythmias: synthesis and evaluation of ibutilide analogues with enhanced metabolic stability and diminished proarrhythmic potential."
06/01/2000 - "New data related to the conversion of this arrhythmia to sinus rhythm is reviewed, namely internal atrial defibrillation with low energy shocks and the efficacy of new drugs such as ibutilide. "
11/03/1992 - "Ibutilide fumarate is currently in Phase II clinical trials for the treatment of life-threatening cardiac arrhythmias. "
05/01/2009 - "Ibutilide treatment was successful in all patients, with the arrhythmia recurring early in 1 patient. "
01/01/2005 - "In all patients, the duration of arrhythmia before treatment was a predictor of arrhythmia termination, although this was more obvious in the group that received ibutilide. "
|4.||Torsades de Pointes (Torsade de Pointes)
06/01/2004 - "Purpose of this study was to determine whether women are more prone to develop ibutilide-induced torsade de pointes. "
09/01/2010 - "The most serious complication of ibutilide is torsades de pointes (TdP). "
04/01/2006 - "In three episodes torsade de pointes occurred after ibutilide (6.1%), requiring defibrillation in two cases (4.1%). "
06/01/2004 - "Incidence of ibutilide-induced torsade de pointes is higher in women than in men. "
06/01/2004 - "There were no reported deaths secondary to torsade de pointes associated with ibutilide infusion. "
04/01/2006 - "We studied the efficacy of ibutilide for acute conversion of monomorphic atrial tachycardia (monoAT) in a prospective, open label study in the intensive care unit of a cardiological clinic. "
10/01/2013 - "These findings may be explained by the progressive destabilization of higher frequency, more homogeneous primary drivers of AF over the course of ibutilide administration, and/or less uniform propagation of atrial activation, until AF maintenance becomes more difficult and either transforms to atrial tachycardia or terminates to SR."
04/01/2006 - "Efficacy and safety of ibutilide for the conversion of monomorphic atrial tachycardia."
12/01/2005 - "High doses of ibutilide may completely terminate all reentrant activity, converting AF to PV tachycardia before the resumption of sinus rhythm."
10/16/2001 - "Ibutilide caused transient loss of the delta wave in 1 patient and abolished inducible tachycardia in 2 patients, although retrograde mapping still allowed for successful AP ablation. "
|4.||Sotalol (Sotalol Hydrochloride)
|9.||Magnesium Sulfate (Sulfate, Magnesium)
|10.||Calcium Channel Blockers (Blockers, Calcium Channel)
|1.||Electric Countershock (Cardioversion)
|5.||Implantable Defibrillators (Implantable Cardioverter-Defibrillator)